GSK unit wins partial dismissal in dostarlimab licence dispute with AnaptysBioProactive Investors • 04/27/26
Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro's Anticipatory Breach ClaimGlobeNewsWire • 04/24/26
Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial CollaborationsGlobeNewsWire • 04/20/26
Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business UpdateGlobeNewsWire • 03/27/26
First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private PlacementGlobeNewsWire • 03/27/26
AnaptysBio, Inc. (ANAB) Presents at Barclays 28th Annual Global Healthcare Conference TranscriptSeeking Alpha • 03/10/26
Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewsWire • 03/03/26
Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular PsoriasisPRNewsWire • 02/25/26
AnaptysBio, Inc. (ANAB) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/14/26
What This Insider Trim at AnaptysBio Means for Investors After a 260% Stock RallyThe Motley Fool • 01/11/26
Anaptys Files Motion to Dismiss Tesaro's Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiaryGlobeNewsWire • 01/08/26
Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular PsoriasisPRNewsWire • 12/15/25
AnaptysBio Buckles After Trading Legal Barbs With Pharma Giant GSKInvestors Business Daily • 11/21/25